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Abstract
Background Hyperpolarized (HP) 13C-pyruvate MRI is a stable-isotope molecular imaging modality that provides real-time
assessment of the rate of metabolism through glycolytic pathways in human prostate cancer. Heretofore this imaging
modality has been successfully utilized in prostate cancer only in localized disease. This pilot clinical study investigated the
feasibility and imaging performance of HP 13C-pyruvate MR metabolic imaging in prostate cancer patients with metastases
to the bone and/or viscera.
Methods Six patients who had metastatic castration-resistant prostate cancer were recruited. Carbon-13 MR examination
were conducted on a clinical 3T MRI following injection of 250 mM hyperpolarized 13C-pyruvate, where pyruvate-to-lactate
conversion rate (kPL) was calculated. Paired metastatic tumor biopsy was performed with histopathological and RNA-seq
analyses.
Results We observed a high rate of glycolytic metabolism in prostate cancer metastases, with a mean kPL value of 0.020 ±
0.006 (s−1) and 0.026 ± 0.000 (s−1) in bone (N= 4) and liver (N= 2) metastases, respectively. Overall, high kPL showed
concordance with biopsy-confirmed high-grade prostate cancer including neuroendocrine differentiation in one case. Interval
decrease of kPL from 0.026 at baseline to 0.015 (s
−1) was observed in a liver metastasis 2 months after the initiation of taxane
plus platinum chemotherapy. RNA-seq found higher levels of the lactate dehydrogenase isoform A (Ldha,15.7 ± 0.7)
expression relative to the dominant isoform of pyruvate dehydrogenase (Pdha1, 12.8 ± 0.9).
Conclusions HP 13C-pyruvate MRI can detect real-time glycolytic metabolism within prostate cancer metastases, and can
measure changes in quantitative kPL values following treatment response at early time points. This first feasibility study
supports future clinical studies of HP 13C-pyruvate MRI in the setting of advanced prostate cancer.
Introduction
Metastatic castration-resistant prostate cancer (mCRPC) is
the most lethal form of the disease, accounting for 31,000
deaths/year in the United States [1]. More than 90% of
patients with mCRPC develop osseous metastases and
nearly half have bone as the only site of the disease [2, 3].
Visceral metastases occur in 10–15% of mCRPC patients
and are associated with high disease burden and poor
prognosis [4, 5]. Despite the emergence of multiple thera-
pies that have been shown to prolong overall survival,
including androgen pathway inhibitors, immunotherapy,
radiopharmaceuticals, and chemotherapeutics, there is an
unmet need for novel therapies to further improve treatment
outcomes [3, 6, 7].
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A limitation to the development of novel systemic thera-
pies in mCRPC, especially with bone predominance without
measurable disease by conventional imaging criteria, is the
lack of validated imaging biomarkers to provide real-time
response monitoring. Automated bone indices of radio-
nuclide bone scans have not been sufficiently prospectively
validated, and provide minimal information with respect to
direct tumor metabolic activity. Also, changes in bone scin-
tigraphy with response to therapy can be slow to occur and
are complicated by flare phenomena and differences in
uptake between sclerotic versus lytic lesions [8]. Newer PET
analogs, including agents targeting prostate-specific mem-
brane antigen, have shown promise as a diagnostic tool, but
have limited and conflicting data to support their use to
monitor therapeutic response and resistance [9, 10].
Hyperpolarized 13C MRI (HP 13C MRI) is a stable-isotope
molecular imaging approach that probes pyruvate-to-lactate
metabolism mediated by the upregulation of LDH enzymatic
activity in cancer due to the Warburg effect [11–14] (Fig. 1).
High glycolytic activity and rapid pyruvate-to-lactate con-
version are signatures of aggressive cancer [13, 15, 16].
There is also a broad consensus that the pharmacologic
action of chemotherapy is tightly coupled with metabolic
pathways, and responses to chemotherapy might be reflected
as modulations of cancer metabolism [17–19]. Heretofore HP
13C-pyruvate MRI has been successfully utilized in prostate
cancer only in localized disease. This imaging modality has
been used to detect metabolic responses to chemohormonal
therapy in primary prostate cancer [20], at earlier time points
than conventional multiparametric MRI.
In the current pilot imaging study, we aimed to broaden
the scope of HP 13C-pyruvate MRI to the metastatic CRPC
setting, with direct visualization of skeletal and visceral
metastases, in order to provide real-time assessment of
tumor metabolism and metabolic response to therapy.
Methods
Patient selection
Key eligibility criteria included histologic evidence of
prostate cancer, progressive mCRPC by PCWG2 criteria
[7], ECOG performance status of 0 or 1, and adequate end
organ function. All patients underwent restaging CT and
bone scans prior to enrollment, and had at least one iden-
tified lesion amenable to HP 13C MRI. Patient recruitment
and HP 13C-pyruvate studies were conducted in compliance
with an IRB-approved protocol (NCT02911467), and all
patients provided written informed consent.
HP 13C patient MRI studies
GMP [1−13C]pyruvic acid (Sigma-Aldrich Isotec, Miamis-
burg OH) was prepared and loaded in pharmacy kits in
accordance with the IRB- and FDA IND-approved stable-
isotope manufacturing process. The pyruvic acid was
polarized in a 5T SPINLab (GE Healthcare, Chicago IL)
clinical trial polarizer for 2.5–3 h. Dissolutions yielded
237 ± 10 mM sterile pyruvate with 37.1 ± 3.2% polarization,
0.6 ± 0.4 μM residual radical and 31.0 ± 0.6 °C temperature,
7.5 ± 0.3 pH, 63 ± 4 s dissolution-to-injection time. A
pharmacist oversaw the automatic quality control and
integrity of the sterilization filter, and released the dose
for injection once sterility and safety criteria were met
[21, 22].
All studies were conducted on a clinical 3T MRI
(MR750, GE Healthcare) equipped with multinuclear
spectroscopy capabilities. A custom surface coil with figure-
eight configuration was applied for both 13C transmit and
receive. A 16-channel abdominal array (GE Healthcare) was
used for proton imaging.
Follow-up 13C-pyruvate MRI was optional after the
initiation of systemic therapy for the treatment of mCRPC.
Data acquisition and analysis
The HP-13C acquisition was conducted using a 2D dynamic
MR spectroscopic imaging pulse sequence with a slice-
selective spectral-spatial excitation, followed by phase-
encode and echo-planar spectroscopic imaging readout [11].
Pulse sequence parameters were as follows: 130 ms/3.5 ms
TR/TE, 2–3 cm slice thickness, 1.2–1.5 cm in plane spatial
and 3 s temporal resolutions, 60 s acquisition window, 545
Hz bandwidth, constant flip angle through time with pyr-
uvate 10°, and lactate 20°. Scan started 5 s following the
end of the injection. Patients were asked to hold their breath
as long as possible, after which they were instructed to
breathe gently and resume breath holding as tolerated.
Conventional proton T1-weighted spoiled gradient-echo
(TR/TE= 4.3 ms/1.9 ms) images were acquired for ana-
tomic reference. Dynamic HP 13C MRI datasets were pro-
cessed by applying even–odd lobe phasing, B0-shift
correction, tensor-low-rank signal enhancement [23], spec-
tral baseline correction [24], followed by a phase-sensitive
peak quantification. The pyruvate-to-lactate conversion rate,
Fig. 1 An illustration of LDH-mediated aerobic glycolysis and rele-
vant metabolic pathways
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kPL, was evaluated using an inputless single-compartment
two-site exchange model [25], and the value reported was
the maximum over ROI of the lesion identified on proton
MRI. Total carbon signal-to-noise ratio (SNR) was reported
as summed SNR of 13C-labeled tracers averaged over time.
The image processing tools are located under—SIVIC
Image Processing/Display: https://sourceforge.net/projects/
sivic, Hyperpolarized MRI Toolbox: https://github.com/La
rsonLab/hyperpolarized-mri-toolbox.
Metastatic tumor biopsy acquisition and analysis
CT-guided metastatic tumor biopsies following HP MRI
acquisition were obtained in five out of the six patients
enrolled in the study (Table 1). Tumor biopsies were
obtained for both fresh frozen processing and formalin fixed
paraffin embedded (FFPE) processing. FFPE tissues were
used for histologic diagnosis, while frozen tissue underwent
Laser Capture Microdissection for RNA-seq profiling as
previously described [6]. Expression levels reported as log
(1+ (TPM × 106)). Processed RNA-seq data are located in
the Supplementary Materials.
Results
Patient characteristics
Six patients were enrolled in this pilot feasibility study. The
baseline characteristics of the patients are shown in Table 1.
All patients had progressive mCRPC at study entry. Five of
the patients underwent CT-guided metastatic tumor biopsy
of the target lesions following completion of baseline 13C-
pyruvate MRI. No adverse events were reported throughout
this study.
HP 13C-pyruvate MRI detects high kPL in bone and
liver metastases
The rate of conversion of pyruvate to lactate (kPL) from
target lesions in each patient is listed in Table 2. There was
high kPL in both bone and liver metastases, with mean kPL of
(0.020 ± 0.006 s−1) and (0.026 ± 0.000 s−1), respectively
[26]. Regions of high kPL were consistent with CT and MRI
radiographic findings of metastatic disease presence, as
shown in the representative kPL image overlays for the target
lesions (Fig. 2a, Supplementary Figs. 1–4).
The liver mass of patient six showed considerable
intratumoral heterogeneity (Supplementary Fig. 4b). Max-
imum kPL= 0.025 (s−1) was found in viable tumor, whereas
kPL= 0.004 (s−1) was observed in a necrotic-appearing
region identified both on CT and the delayed phase of
contrast T1-weighted images. T
ab
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Table 2 also summarizes the total carbon SNR for each
study. The total carbon SNR was 117 ± 126 in bone
metastases (N= 4), and 85 ± 7 between liver involvements
(N= 2). In general, the SNR in all cases was adequate for
reliable kPL fitting (standard error metric σkPL= 0.005 ±
0.003) [27].
In all five patients with paired 13C-pyruvate MRI and
CT-guided biopsy of the target lesions, the histological
evidence of metastatic prostate cancer was detected. In four
of the five cases, the histology demonstrated poorly differ-
entiated adenocarcinoma. In one patient (Patient 1), the
paired metastatic tumor biopsy demonstrated discrete
regions of adenocarcinoma and treatment-emergent small
cell neuroendocrine differentiation (Fig. 2b) [6].
Higher levels of gene expression of the lactate dehy-
drogenase isoform A (Ldha,15.7 ± 0.7) relative to the
dominant isoform of pyruvate dehydrogenase (Pdha1, 12.8
± 0.9) were detected on RNA-seq of the target metastatic
biopsies (Table 2), consistent with enhanced aerobic gly-
colysis detected in the rate of conversion of pyruvate to
lactate on HP 13C MRI. No significant difference in Ldha or
Pdha1 expression was observed in the patients imaged in
this study compared with a previously published cohort of
metastases from 200 men with mCRPC (Ldha: 15.1 ± 1.1,
p > 0.17; Pdha1: 12.0 ± 0.9, p > 0.06, Wilcoxon ranked sum
test) [6].
HP 13C MRI detected a metabolic rate decrease in a
metastasis following chemotherapy
Patient 2 had mCRPC with liver metastases and low serum
PSA level. Carboplatin+ docetaxel chemotherapy was
started 24 days after the baseline HP 13C MRI study
(Fig. 3c). Follow-up HP MRI study 62 days after the
Table 2 Findings from HP 13C MRI including kPL, and RNA
expression of key genes
Patient kPL of target
lesion (s−1)
Ldha/Pdha1
expression (in log)
SNR tCarb
1 0.013 15.4/12.3 290.3 ± 248.5
2 Baseline: 0.026
Follow-upa: 0.015
16.2/13.8 Baseline: 89.7 ± 40.9
Follow-upa: 77.7
3 0.017 Not acquired 131.4 ± 10.2
4 0.026 14.7/11.6 27.4 ± 9.9
5 0.023 16.4/12.6 19.5 ± 3.6
6 0.025 15.6/13.7 88.2 ± 26.1
SNR tcarb: summed SNR of 13C-labeled tracers averaged over time
aFollow-up was 2 months after initiation of carboplatin+ docetaxel
Fig. 2 a Patient 1 (75 years old) was diagnosed with metastatic
castration-resistant prostate cancer with several large osteoblastic
lesions throughout the left hemipelvis and involving left femur. CT
identified a relatively osteolytic lesion in left ilium (Green arrows),
measuring 9.9 × 4.1 cm. The lesion was infiltrative, causing destruction
of the bone cortex and extension into the surrounding soft tissues. T1-
weighted (T1w) spoiled gradient-echo MRI was used to target the same
lesion observed on CT for the HP 13C MR acquisition. Regions of high
pyruvate-to-lactate conversion rate (kPL) correlated with the osseous
lesion on CT and hypointensity on T1w MRI. kPL was estimated 0.013
(s−1). b The paired bone biopsy demonstrated discrete regions of
adenocarcinoma and treatment-emergent small cell neuroendocrine
differentiation
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initiation of treatment demonstrated a 42% decrease in
pyruvate-to-lactate conversion rate kPL, from 0.026 to 0.015
s−1, in the target liver lesion (Fig. 3a). This was accom-
panied by interval decrease of the lesion size (Fig. 3b,
19.3–11.8 mm, 39%) based on RECIST 1.1 criteria, along
with serum PSA decline of >50% from baseline (38–13.4
ng/ml), consistent with systemic treatment response.
Discussion
This work reports the results of the first-ever pilot imaging
study of prostate cancer metastases using HP 13C-pyruvate
MRI. This study demonstrates the feasibility of detecting
real-time metabolic activity of metastases and capture
therapeutic response with this emerging stable-
isotope molecular imaging method. Correlation with
paired metastatic biopsy demonstrated high-grade prostate
adenocarcinoma, including in one case, evidence of neu-
roendocrine differentiation.
The high pyruvate-to-lactate conversion rate, kPL, via
upregulated LDH activity in cancer, known as Warburg
effect, reflects cancer aggressiveness, and decrease in kPL
can reflect therapeutic response [14, 20]. Overall, the
pyruvate-to-lactate conversion rate kPL found in bone
(0.020 ± 0.006 s−1) and liver (0.026 ± 0.000 s−1) lesions was
either higher than or comparable with that of high-grade
primary prostate cancer (0.013 ± 0.003 s−1) in a cohort
imaged prior to radical prostatectomy with whole mount
section pathologic correlation [26]. These high kPL values
were correlated with the metastatic biopsy findings of high-
grade adenocarcinoma or mixed high-grade adenocarci-
noma and small cell neuroendocrine phenotypes in the
patients studied in this report.
Elevated Ldha expression in prostate cancer is known to
be associated with aggressive phenotypes and resistant to
Fig. 3 Patient 2 (57 years old)
was diagnosed with CRPC that
metastasized to liver. The patient
was previously treated with
enzalutamide and an
investigational agent (BET
inhibitor, phase I) with clinical
progression. Chemotherapy of
carboplatin and docetaxel started
~1 month post baseline HP 13C
scan, and follow-up was
2 months after initiation of
therapy. a A decrease in
pyruvate-to-lactate conversion
rate kPL was observed from
0.026 to 0.015 (s−1) after
2 months of chemotherapy. Note
the increase in pyruvate and
lactate at 50–60 s post injection.
Most likely this is predominately
due to vascular contributions
coming from intestines. b
Follow-up 2 months after
initiation of therapy found a
decrease in lesion size
(19.3–11.8 mm) indicating
therapeutic response based on
RECIST criteria. c In addition,
serum PSA decreased from
38–13.4 ng/ml also indicating
therapeutic response. HA arterial
phase, PV portal venous phase
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therapy [28–30]. The high Ldha expression relative to
Pdha1 in this study was consistent with a larger published
mCRPC cohort [6], reflective of enhanced aerobic glyco-
lysis, whereas in normal prostate epithelial cells the glucose
metabolism favors oxidative phosphorylation, and Pdha1
expression should predominate (Fig. 1). This suggested that
the metabolic features observed in this study using HP 13C-
pyruvate MRI could potentially serve as a representative
cross-section of a much larger patient population with dif-
ferent metastatic sites and types of cell morphology.
A previous study in primary prostate cancer indicated
that kPL reflected early response and resistance to androgen
pathway inhibition [20]. In this communication we
observed a correlation between decreased kPL and clinical
response to the combination of platinum plus taxane che-
motherapy in a patient with mCRPC. Although preliminary,
these findings suggest that imaging metabolic signatures
using HP 13C-pyruvate MR could potentially report
responses to a broader range of oncogenic pathway inhibi-
tion and drug targets, and may be less susceptible to the
upregulation of membrane protein expression secondary to
ADT [31, 32]. These data suggest that the prospective
evaluation of HP 13C-pyruvate as a response biomarker in
mCRPC patients treated with AR-targeting and cytotoxic
chemotherapy is warranted.
Spatially, regions of high kPL showed good alignment
with radiographic findings of metastases using bone scan,
CT, and proton MRI. Temporally, the time-to-peak of
pyruvate bolus was 29 ± 3 s in pelvic bone cases, 23 s in the
rib case, 34 ± 4 s among the liver cases. The bolus delivery
timing was generally consistent with contrast CT/MRI [33],
and are deemed reasonable in light of hemodynamic var-
iations between subjects, and also the vitals of individual
subject at the time of the scan. The inputless kPL model
applied in this study is relatively immune to variations in
bolus characteristics [25].
Differential kPL was observed between viable and
necrotic-appearing regions of Patient 6’s liver lesion (Sup-
plementary Fig. 4b). These findings are consistent with
other emerging reports of intra- and inter-tumoral hetero-
geneity in mCRPC [34] and highlight the potential utility of
this imaging tool to clarify tumor biology with real-time
metabolic monitoring [34–37]. The kPL heterogeneity
between metastatic sites/individual patients and its biolo-
gical underpinning calls for future investigation.
This study also demonstrated that this technology can
provide quantitative metrics of the delivery/uptake of the
injected hyperpolarized carbon isotope by measuring the
total carbon SNR summing the 13C signal observed from
the hyperpolarized pyruvate bolus and downstream meta-
bolic products. Conceptually similar to SUV in PET, total
carbon SNR is a metric of delivery and uptake. Of the
pelvic bone involvements, patient 1, whose lesion appeared
relatively more lytic on CT (Fig. 2a), had higher mean total
SNRPatient 1= 290 versus the other two cases (SNRPatient 4=
27.4, SNRPatient 5= 19.5) with more sclerotic appearances
(Supplementary Figs. 1 and 3). This presents an intriguing
concordance with PET literature in which osteolytic lesions
have shown higher FDG uptake compared with osteoblastic
ones [38–40] and glucose metabolism is known to be dif-
ferently regulated in sclerotic versus lytic diseases [41].
Several key limitations should be identified for this pilot
study. The correlation between metabolic biomarker kPL and
total carbon SNR is yet to be elucidated in the mCRPC
setting. In addition, the test–retest repeatability data are also
needed moving forward. While the total carbon SNR reports
tracer pharmacokinetics at each metastatic site, its quanti-
tative accuracy can be further enhanced using automatic B1
calibration and correction for QC parameters. This study
utilized a 2D single-slice imaging strategy. Future
advancement in array receiver hardware [42] and MR
acquisition sequences [21, 43] will enable full 3D coverage
of the abdomen/pelvis and seamless integration with
standard-of-care restaging scans. Dissemination of this
technology, in terms of infrastructure and instruments,
requires a clinical 13C polarizer and specialized MRI hard-
ware. The on-site pharmaceutical manufacturing follows the
same standard as PET, allowing for shared facility [14].
These capabilities can readily be instated in high-volume
tertiary centers who manages the majority of the advanced
prostate cancer cohort. Overall, future developments are
warranted to address the technical needs including hard-
ware, image acquisition and quantitative analyses, and the
clinical inquiries deserve to be powered by a larger
cohort study.
These preliminary results highlight the future need to
metabolically characterize lymphadenopathy using HP 13C-
pyruvate MRI, as management of nodal disease could be
essential in the realm of biochemically recurrent and oli-
gometastatic PCa [44–47]. For these cohorts of patients,
opportunities for curative treatment are more available, and
clinical outcomes are generally better than those with bone
involvement and thus higher disease burden. Such future
studies could be enabled by the aforementioned technical
advancements to achieve higher resolution and sensitivity,
and new pharmacy QC procedures that reduce HP 13C-
pyruvate time-to-injection and thereby improving
SNR [14].
Conclusions
This pilot study evaluated the safety and feasibility to
conduct HP 13C MRI studies of patients with metastatic
prostate cancer to the skeleton and viscera, which represents
the most advanced and lethal form of the disease. Methods
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were examined and established for instrumentation setup,
pharmacy manufacturing, image acquisition, and quantita-
tive analysis. Safety was demonstrated and highly upregu-
lated pyruvate-to-lactate conversion kPL was observed on
aggressive osseous and hepatic metastases. Interval
decrease of kPL was found for one patient receiving com-
bination chemotherapy, in concordance with conventional
clinical biochemical and imaging biomarkers. These find-
ings warrant further development and investigation of HP
13C-pyruvate MRI in a larger prospective group of men with
metastatic CRPC.
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